Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 281Thoracic 125Gastrointestinal 108Gynecologic 107Genitourinary 75Head & Neck 74Dermatologic 48Sarcoma 21Other solid neoplasm 19Lymphoid 12Endocrine 4Other hematologic neoplasm 3CNS 3Plasma cell 2NET 1

Conditions

Neuroendocrine Tumors 60Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 6Breast Neoplasms 6Pheochromocytoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Adenoma, Islet Cell 5Urinary Bladder Neoplasms 4Thyroid Neoplasms 4Paraganglioma 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Neuroendocrine 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Carcinoma, Medullary 3Adrenocortical Carcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Sarcoma 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × NET × Clear all
NCT06577987 2025-09-15

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Circle Pharma

Phase 1 Recruiting
220 enrolled
BreastEndocrineNETThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡